This is a single agent, prospective, open-label, monocenter, phase II trial of sorafenib in
patients with recurrent and/or metastatic salivary gland carcinoma. This trial will be
conducted with the primary aim to determine the response rate (CR+PR) according to the RECIST
criteria. Response rate according to CHOI criteria, correlation between CHOI criteria and
outcome, disease Control Rate (DCR) and acute toxicity will be evaluated as secondary
objectives.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano